FINGER ALISON CECILY
CIK: 0001731164
Associated companies
Transaction History
| ADMA | ▲ Buy | Grant | 10,690 | $0 | 2/9/2026 | View on chart |
| ADMA | ▲ Buy | Grant | 10,889 | $0 | 2/19/2025 | View on chart |
| ADMA | ▲ Buy | Grant | 24,040 | $0 | 2/26/2024 | View on chart |
| ADMA | ▲ Buy | Grant | 10,690 | $0 | 2/9/2026 | View on chart |
| ADMA | ▲ Buy | Grant | 10,889 | $0 | 2/19/2025 | View on chart |
| ADMA | ▲ Buy | Grant | 24,040 | $0 | 2/26/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.